The US Food and Drug Administration (US FDA) has approved Moderna’s mRNA respiratory syncytial virus (RSV) vaccine for adults 60 and older. According to the FDA, it no longer sought the input of the agency’s independent vaccine advisory committee because it did not foresee any issues or controversial issues arising from its decision.

The product, marketed under the name mResvia, will provide Moderna with a second revenue stream, and the company predicts it will earn $10 billion.

Meanwhile, the company said this about the FDA decision: “The FDA approval of our second product, mRESVIA, builds on the strength and versatility of our mRNA platform.” Moderna is currently negotiating with the US government to fund the late-stage trial of its mRNA bird flu vaccine.

Editor’s Note: Maybe the FDA thought that approving mResvia would not cause much noise since it would only impact individuals already at the end of their lives. What blatant disrespect for life these people have!

Read Original Article